Cureon : a new home for MedTech & BioTech – featuring SBMC’s Pilot Production Facility

On the official opening photo from left to right: Otto van den Boogaard (High Tech Campus Eindhoven) Naomi Verstraeten (Brainport Development), Martijn van Gruijthuijsen (Provincial Executive Province Noord-Brabant), Brigit van Dijk – van de Reijt (BOM, Brabant Development Agency), Jan Rietsema (SBMC) and Quirine Verstappen (Brainport Development)

Eindhoven, October 1, 2025

Today, in front of a full house, Cureon – the new Innovation Center for MedTech and BioTech – officially opened its doors at High Tech Campus Eindhoven.The initiative, driven by High Tech Campus Eindhoven, Smart BioMaterials Consortium (SBMC), Brainport Development, and Brabant Development Agency (BOM), marks a major step forward for healthcare innovation in the region.

Located in building HTC 11, Cureon unites shared workspaces, laboratories, and advanced production facilities to accelerate the journey from research to real-world medical applications. By combining infrastructure, expertise, and collaboration, Cureon strengthens the region’s position as a European frontrunner in MedTech and BioTech innovation.

SBMC’s Pilot Production Facility: From Lab to Life

At the heart of Cureon are SBMC’s GMP-compliant cleanrooms (ISO 6/7) and laboratories – a 400 m² Pilot Production Facility dedicated to scaling biomaterial-based implants and regenerative medicine technologies.

These facilities provide innovators with:

• Immediate access to GMP cleanrooms without the cost or delay of building their own infrastructure.
• Flexible short- or long-term rental options aligned with project needs.
• Technical and regulatory support, including Quality Management as a Service (QMaaS).

Alongside the cleanrooms, SBMC offers a development lab equipped with advanced tools for biomaterials and tissue engineering, such as confocal microscopy, electrospinning, SEM-EDX, tensile testing, and biocompatibility workflows.

“Our GMP-compliant cleanrooms enable companies to develop and produce under conditions required for clinical use. For start-ups, access to these facilities and our expertise can significantly shorten time to market,” says Jan Rietsema, CEO of SBMC. “Being part of Cureon means we are directly connected to a vibrant ecosystem of universities, hospitals, biotech and medtech entrepreneurs. This combination of infrastructure and collaboration creates a powerful environment where new biomaterials and medical devices can move faster from lab to life – ultimately benefitting patients worldwide.”